UPC vs. VIRX, ATXI, BPTSY, BIOR, MYMD, KRBP, VRPX, TFFP, VINC, and TCBP
Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Biophytis (BPTSY), Biora Therapeutics (BIOR), MyMD Pharmaceuticals (MYMD), Kiromic BioPharma (KRBP), Virpax Pharmaceuticals (VRPX), TFF Pharmaceuticals (TFFP), Vincerx Pharma (VINC), and TC Biopharm (TCBP). These companies are all part of the "pharmaceutical products" industry.
Universe Pharmaceuticals vs.
Viracta Therapeutics (NASDAQ:VIRX) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.
Viracta Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Viracta Therapeutics presently has a consensus price target of $4.06, indicating a potential upside of 21,859.46%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Viracta Therapeutics is more favorable than Universe Pharmaceuticals.
Viracta Therapeutics received 29 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
Universe Pharmaceuticals has higher revenue and earnings than Viracta Therapeutics.
In the previous week, Viracta Therapeutics' average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.
Universe Pharmaceuticals' return on equity of 0.00% beat Viracta Therapeutics' return on equity.
31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Universe Pharmaceuticals beats Viracta Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Universe Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Universe Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:UPC) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy UPC Stock Free UPC Stock Alerts